<DOC>
	<DOCNO>NCT00924911</DOCNO>
	<brief_summary>Part 1 study assess relative bioavailability GSK1322322 administer one three investigational tablet compare powder bottle formulation . Pharmacokinetics three tablet evaluate investigation tablet optimal PK profile progress Part 2 . In Part 2 investigational tablet select Part 1 coadministered food alone , H2 blocker alone , H2 blocker give combination ascorbic acid evaluate effect GSK1322322 pharmacokinetics . Plasma GSK1322322 PK profile , safety , tolerability assess dose group .</brief_summary>
	<brief_title>Relative Bioavailability Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>The subject healthy . Male female 18 65 year age inclusive , time signing informed consent . A female eligible enter participate study Nonchildbearing potential Male subject must agree use one contraception method list protocol Body weight great equal 50 kg body mass index 18.529.9 kg/m2 inclusive . Capable give write informed consent QTcB le 450 msec ; QTc le 480 msec subject Bundle Branch Block Screening ECG . AST , ALT , alkaline phosphatase bilirubin less equal 1.5xULN ( isolate bilirubin great 1.5xULN acceptable bilirubin fractionate direct bilirubin le 35 % ) The subject positive prestudy drug/alcohol screen . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive test HIV antibody . History regular alcohol consumption within 6 month study define protocol . The subject participate clinical trial receive investigational product within following time period prior dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive human chorionic gonadotropin test screen prior dosing . Lactating female . Subjects asthma history asthma within past 6 month . History smoke history regular use tobacco nicotinecontaining product within 3 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice , pummelo , satsuma , ugli , tangerine , tangelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GSK1322322 , relative bioavailability , single dose , food effect , H2 blocker , healthy subject , open label , PIB , tablet</keyword>
</DOC>